论文部分内容阅读
肝性脑病是各种肝脏疾病的晚期并发症(在我国主要是慢性乙型肝炎引起),其发病机制至今未完全明了,其中以氨中毒理论的研究最多,最确实有据。因此对肝性脑病的治疗最可行的方法是降低血液和组织里的氨浓度。雅博司被认为可有效降低血氨和减少肝脏受损而达到防治肝性脑病目的的药物。我们对31例乙型肝炎并发不同程度的肝性脑病患者应用雅博司的治疗情况进行了临床疗效观察。
Hepatic encephalopathy is a late complication of various liver diseases (caused mainly by chronic hepatitis B in our country). The pathogenesis of hepatic encephalopathy is not fully understood so far. Among them, the most studied and most accurate evidence is the theory of ammonia poisoning. Therefore, the most viable approach to the treatment of hepatic encephalopathy is to reduce the concentration of ammonia in the blood and tissues. Arxob is considered as a drug that can effectively reduce blood ammonia and reduce liver damage to achieve the purpose of prevention and treatment of hepatic encephalopathy. We have 31 cases of hepatitis B complicated by different degrees of hepatic encephalopathy in patients with therapeutic application of Arnebia clinical efficacy.